{
  "main_header": {
    "sid": 1003405,
    "name": "Rossari Biotech",
    "stock_name": "Rossari Biotech",
    "full_name": "Rossari Biotech Ltd",
    "name_url": "stocks-analysis/rossari-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "509.50",
    "chg": -3.25,
    "chgp": "-0.63%",
    "dir": -1,
    "prev_price": "512.75",
    "mcapval": "2,808.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543213,
    "symbol": "ROSSARI",
    "ind_name": "Specialty Chemicals",
    "ind_code": 11,
    "indexname": "India SENSEX",
    "isin": "INE02A801020",
    "curr_date": "Aug 10",
    "curr_time": "",
    "bse_nse_vol": "38.24 k",
    "exc_status": "Active",
    "traded_date": "Aug 10, 2026",
    "traded_date_str": "2026 08 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/rossari-biotech-1003405-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Rossari Biotech Valuation Shifts to Very Attractive Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rossari-biotech-valuation-shifts-to-very-attractive-amid-market-challenges-3997908",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/RossariBiotechL_valuationdot_3997908.png",
        "date": "2026-05-19 08:02:37",
        "description": "Rossari Biotech Ltd, a small-cap player in the Specialty Chemicals sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price pressures and a challenging industry backdrop, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling entry points relative to its historical averages and peer group, signalling a potential opportunity for discerning investors."
      }
    ],
    "total": 15,
    "sid": "1003405",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/rossari-biotech-1003405"
  },
  "announcements": [
    {
      "caption": "Update On Investor Call.",
      "datetime": "06-Aug-2026",
      "details": "",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "03-Aug-2026",
      "details": "Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "24-Jul-2026",
      "details": "Intimation of Transcript of Q1 FY 27 for the Earnings Conference Call held on July 20 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Rossari Biotech Ltd has declared <strong>25%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Rossari Biotech Valuation Shifts to Very Attractive Amid Market Challenges

2026-05-19 08:02:37

Rossari Biotech Ltd, a small-cap player in the Specialty Chemicals sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price pressures and a challenging industry backdrop, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling entry points relative to its historical averages and peer group, signalling a potential opportunity for discerning investors.

Read More

View All News